The TRIPP study is the first RCT and key to opening reimbursement.
If TRIPP is positive and PANCoSIL is positive then there will be value for an acquirer who will go straight into an FDA approved study. In 3 years they will have the product in US and EU will be paying the bills in the meantime.
The company will be worth a lot more to an acquirer than the current sp.
That’s the simple value equation for me.
Ann: First Patient in Australia Randomised in TRIPP-FFX Trial, page-13
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.010(1.06%) |
Mkt cap ! $13.51M | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | $1.02 | 94.0¢ | $110.7K | 114.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15628 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 1909 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |